Alnylam Pharmaceuticals, Inc. (ALNY) Shares Sold by Dodge & Cox

The firm owned 9,185,820 shares of the biopharmaceutical company’s stock after selling 213,425 shares during the period. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.12). Neuberger Berman Group LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth about $229,000. Over the last week of the month, it was 44.49%, 34.49% over the last quarter, and 112.36% for the past six months. It is down 33.54% since September 22, 2016 and is uptrending.

Boussard & Gavaudan Investment Management Llp increased its stake in Reynolds American Inc (RAI) by 7.52% based on its latest 2017Q2 regulatory filing with the SEC. The stock’s market capitalization is $10.44 billion. Traders acquired 30,530 call options on the company. Benjamin F Edwards & invested in 0% or 27 shares.

Investors sentiment increased to 1.52 in Q2 2017. Its up 0.70, from 0.82 in 2017Q1.

Many analysts have provided their estimated foresights on Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company.

As of the end of the quarter Rhenman & Partners Asset Management Ab had disposed of 49,810 shares trimming its position 38.3%. Teachers Retirement Of The State Of Kentucky accumulated 149,218 shares. At present, 5 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. Federated Invsts Incorporated Pa, a Pennsylvania-based fund reported 62,293 shares. The short sellers then promise to replace the stock in the future and makes dividend payments out of their own pockets to cover the dividend income that is no longer exists on the original, now borrowed and sold, shares. State of Wisconsin Investment Board raised its stake in shares of Alnylam Pharmaceuticals by 0.7% during the 2nd quarter. (NASDAQ:ALNY)’s stock was 201.60%. Winfield Assocs holds 0% or 5 shares in its portfolio. It also reduced its holding in Sage Therapeutics Inc (Put) (NASDAQ:SAGE) by 248,400 shares in the quarter, leaving it with 51,600 shares, and cut its stake in Myovant Sciences Ltd. Therefore 59% are positive.

Wall Street await Alnylam Pharmaceuticals, Inc. Recently, analysts have updated the overall rating to 2.2. PNC Financial Services Group Inc. now owns 8,685 shares of the biopharmaceutical company’s stock worth $446,000 after buying an additional 36 shares in the last quarter. The firm earned “Buy” rating on Tuesday, July 11 by Cowen & Co. The company was maintained on Thursday, September 7 by Piper Jaffray. JP Morgan upgraded Alnylam Pharmaceuticals, Inc. Nomura initiated the shares of ALNY in report on Friday, September 15 with “Sell” rating. Dodge & Cox owned 10.66% of Alnylam Pharmaceuticals worth $732,661,000 as of its most recent filing with the SEC. ALNY has a 1-week performance of 41.29%. Is Slipping Today” on September 07, 2017, also with their article: “Premarket analyst action – healthcare” published on September 21, 2017, published: “SHAREHOLDER ALERT: “Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” on September 07, 2017.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Wednesday, August 9th. $21.38M worth of stock was bought by Sanofi on Wednesday, May 31. (NASDAQ:ALNY). Cap World Invsts has 137,700 shares. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth approximately $148,000. The forecast of 10 surveyed investment analysts covering the stock advises investors to Buy stake in the company. The firm has “Market Outperform” rating by JMP Securities given on Wednesday, March 9. Finally, Barclays PLC raised their price objective on Alnylam Pharmaceuticals from $50.00 to $70.00 and gave the company an “equal weight” rating in a research note on Thursday, August 10th. The firm has “Neutral” rating by Citigroup given on Wednesday, January 18. The median estimate represents a -13.04% decrease from the last price of 113.84. This assists to give a return figure that has a stronger focus on the most current period and is thus a better measure for short-term analysis.

Leave a Reply

Your email address will not be published. Required fields are marked *